PAVmed is outlining near-term plans for its Veris implantable device submission to the FDA, while Lucid Diagnostics’ EsoGuard cancer screening test reaches broader Medicare reimbursement coverage.
According to one report, PAVmed points to an early 2027 timeline for a Veris 510(k) submission and also notes Lucid has secured Medicare reimbursement for EsoGuard, framing these developments as key commercial and regulatory milestones. A separate business update adds additional operational detail, stating that Veris design work has moved to a design-freeze stage, that a 90-day GLP animal study has begun, and that PAVmed is engaging with the FDA on other programs. It also reports preliminary third-quarter 2026 financial results.
Across the sources, the main differences are emphasis: one focuses tightly on the Veris submission schedule alongside the EsoGuard reimbursement outcome, while the other pairs that context with broader program progress and preliminary financial performance. Both present the same overarching storyline of advancing regulatory preparation for Veris and expanding reimbursement for EsoGuard.